tyrosyl-isoleucyl-glycyl-seryl-arginine has been researched along with pa22-2 in 1 studies
| Studies (tyrosyl-isoleucyl-glycyl-seryl-arginine) | Trials (tyrosyl-isoleucyl-glycyl-seryl-arginine) | Recent Studies (post-2010) (tyrosyl-isoleucyl-glycyl-seryl-arginine) | Studies (pa22-2) | Trials (pa22-2) | Recent Studies (post-2010) (pa22-2) |
|---|---|---|---|---|---|
| 111 | 0 | 29 | 8 | 0 | 0 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gomez, DE; Mackay, AR; Nason, AM; Thorgeirsson, UP | 1 |
1 other study(ies) available for tyrosyl-isoleucyl-glycyl-seryl-arginine and pa22-2
| Article | Year |
|---|---|
Studies on the effects of laminin, E-8 fragment of laminin and synthetic laminin peptides PA22-2 and YIGSR on matrix metalloproteinases and tissue inhibitor of metalloproteinase expression.
Topics: Amino Acid Sequence; Animals; Cell Line; Collagenases; Fibrosarcoma; Gene Expression; Glycoproteins; Humans; Laminin; Melanoma; Metalloendopeptidases; Mice; Molecular Sequence Data; Oligopeptides; Peptide Fragments; Peptides; Protein Biosynthesis; Tissue Inhibitor of Metalloproteinase-2; Tissue Inhibitor of Metalloproteinases; Tumor Cells, Cultured | 1994 |